BGLC
BEARISH
$3.12
Live
BioNexus Gene Lab Corp. · NASDAQ
$2.01
52W Range
$15.6
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$7.38M
P/E
N/A
ROE
-28.3%
Profit margin
-24.3%
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
The Advanced Deterministic Scorecard reveals a critically weak financial health with a Piotroski F-Score of 0/9, indicating severe deterioration in fundamental performance. Despite a low Price/Book and Price/Sales ratio suggesting potential value, the company is unprofitable with negative margins, declining revenue, and a disastrous five-year return of -98.9%. Strong liquidity ratios are overshadowed by an inability to generate profits or positive cash flow, while insider sentiment is neutral at best. The absence of Altman Z-Score and Graham Number prevents definitive valuation anchoring, but overwhelming evidence points to operational distress and high investment risk.
Key Strengths
Exceptionally high Current Ratio (8.30) indicating strong short-term liquidity
Very low Debt/Equity ratio (0.03) suggesting minimal leverage risk
Quick Ratio of 6.81 reflects substantial liquid assets relative to liabilities
Trading below book value (P/B of 0.82) may attract deep value or distressed investors
Current price near 52-week low could present speculative entry point for turnaround bets
Key Risks
Piotroski F-Score of 0/9 signals extreme financial weakness and high risk of continued underperformance
Negative profit and operating margins (-24.27%, -30.26%) show persistent unprofitability
Revenue declining YoY by 3.30% amid sector peers growing on average 18.78%
Lack of Altman Z-Score and EV/EBITDA data increases uncertainty and potential hidden distress
Five-year return of -98.9% indicates near-total loss of shareholder value with no recovery trend
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
14
Weak
45
10
5
8
0
AI Verdict
Extremely high-risk investment with critical financial deterioration and no clear catalyst for recovery.
Key drivers: Piotroski F-Score of 0/9, Negative profitability across all metrics, Revenue contraction in declining market context, Absence of analyst coverage and target pricing
Confidence
96%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Low Price/Book (0.82) implies trading below asset value
- Price/Sales of 0.78 is below sector average
Watchpoints
- No Graham Number or Intrinsic Value available for validation
- P/E and Forward P/E are N/A due to unprofitability
Future
10/100
Ref Growth rates
Positives
No standout positives identified.
Watchpoints
- Revenue Growth (YoY) is negative at -3.30%
- No earnings or cash flow growth data available
- Sector peers show strong growth while BGLC contracts
Past
5/100
Ref Historical trends
Positives
No standout positives identified.
Watchpoints
- 5Y price change of -98.9% shows catastrophic decline
- 1Y return of -9.3% continues downward trend
- 6M and 1M returns show accelerating losses
Health
8/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity ratio of 0.03 indicates minimal financial leverage
Watchpoints
- Piotroski F-Score of 0/9 indicates severe financial distress
- ROE of -28.35% and ROA of -16.43% reflect poor capital efficiency
- No Altman Z-Score available, increasing risk uncertainty
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100 indicates no dividend program
- No yield, payout, or ex-dividend data available
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.12
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BGLC and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BGLC
BioNexus Gene Lab Corp.
Primary
|
-98.9% | -97.4% | -9.3% | -36.3% | -24.8% | -14.2% |
|
GURE
Gulf Resources, Inc.
Peer
|
-90.4% | -81.3% | -35.8% | -6.5% | +11.0% | -33.7% |
|
SNES
SenesTech, Inc.
Peer
|
-100.0% | -99.1% | -17.9% | -57.5% | -16.7% | 0.0% |
|
JCTC
Jewett-Cameron Trading Company Ltd.
Peer
|
-84.2% | -69.6% | -54.7% | -51.0% | -6.6% | +0.6% |
|
CAPS
Capstone Holding Corp.
Peer
|
-98.4% | -98.5% | -69.5% | -53.3% | -11.7% | -17.0% |
BGL
BioNexus Gene Lab Corp.
Primary
5Y
-98.9%
3Y
-97.4%
1Y
-9.3%
6M
-36.3%
1M
-24.8%
1W
-14.2%
GUR
Gulf Resources, Inc.
Peer
5Y
-90.4%
3Y
-81.3%
1Y
-35.8%
6M
-6.5%
1M
+11.0%
1W
-33.7%
SNE
SenesTech, Inc.
Peer
5Y
-100.0%
3Y
-99.1%
1Y
-17.9%
6M
-57.5%
1M
-16.7%
1W
0.0%
JCT
Jewett-Cameron Trading Company Ltd.
Peer
5Y
-84.2%
3Y
-69.6%
1Y
-54.7%
6M
-51.0%
1M
-6.6%
1W
+0.6%
CAP
Capstone Holding Corp.
Peer
5Y
-98.4%
3Y
-98.5%
1Y
-69.5%
6M
-53.3%
1M
-11.7%
1W
-17.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
0.82
P/S Ratio
0.78
EV/Revenue
0.31
EV/EBITDA
-1.26
Market Cap
$7.38M
Profitability
Profit margins and return metrics
Profit Margin
-24.27%
Operating Margin
-30.26%
Gross Margin
14.77%
ROE
-28.35%
ROA
-16.43%
Growth
Revenue and earnings growth rates
Revenue Growth
-3.3%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
8.3
Strong
Quick Ratio
6.81
Excellent
Cash/Share
$1.61
Basic Materials Sector Comparison
Comparing BGLC against 143 companies in the Basic Materials sector
(14 bullish, 54 neutral, 75 bearish)
Return on Equity (ROE)
-28.35%
This Stock
vs
-6.64%
Sector Avg
+327.0%
(Excellent)
Profit Margin
-24.27%
This Stock
vs
-5.75%
Sector Avg
+321.8%
(Superior)
Debt to Equity
0.03
This Stock
vs
0.89
Sector Avg
-96.1%
(Less Debt)
Revenue Growth
-3.3%
This Stock
vs
36.56%
Sector Avg
-109.0%
(Slower)
Current Ratio
8.3
This Stock
vs
5.16
Sector Avg
+60.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BGLC
BioNexus Gene Lab Corp.
|
BEARISH | $7.38M | - | -28.3% | -24.3% | $3.12 | |
|
GURE
Gulf Resources, Inc.
|
BEARISH | $7.91M | - | -43.4% | -286.8% | $5.14 | Compare |
|
SNES
SenesTech, Inc.
|
BEARISH | $8.49M | - | -105.7% | -287.4% | $1.6 | Compare |
|
JCTC
Jewett-Cameron Trading Company Ltd.
|
BEARISH | $5.98M | - | -36.1% | -18.2% | $1.7 | Compare |
|
CAPS
Capstone Holding Corp.
|
BEARISH | $5.05M | - | -20.2% | -12.4% | $0.56 | Compare |
BGLC
BioNexus Gene Lab Corp.
BEARISH
Mkt Cap
$7M
P/E
-
ROE
-28.3%
Price
$3.12
Past News Coverage
Recent headlines mentioning BGLC from our newsroom.
Newest → oldest
No matching news yet.